Anzeige
Mehr »
Donnerstag, 31.07.2025 - Börsentäglich über 12.000 News
Geheime Millionen-Käufe in Bitcoin & Altcoins - ohne Wallet, ohne Risiko? Jetzt wird's spannend
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CMJ9 | ISIN: US16385C1045 | Ticker-Symbol: 2QV0
Tradegate
30.07.25 | 20:13
0,965 Euro
+2,66 % +0,025
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CHEMOMAB THERAPEUTICS LTD ADR Chart 1 Jahr
5-Tage-Chart
CHEMOMAB THERAPEUTICS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,9150,96530.07.

Aktuelle News zur CHEMOMAB THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrChemomab Therapeutics Ltd. - 6-K, Report of foreign issuer4
01.07.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer3
CHEMOMAB THERAPEUTICS Aktie jetzt für 0€ handeln
30.06.Chemomab Therapeutics: Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'2511
15.05.Chemomab Hikes on Q1 Figures4
15.05.Chemomab Therapeutics GAAP EPS of -$0.01 in-line4
15.05.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer2
28.04.Chemomab reports promising PSC treatment data4
28.04.Chemomab Therapeutics: Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases1
15.04.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer1
04.04.Chemomab Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers3
27.03.Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease1
27.03.Chemomab Therapeutics: Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers160Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients...
► Artikel lesen
20.03.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer2
03.03.Chemomab Therapeutics GAAP EPS of -$0.011
03.03.Chemomab Therapeutics Ltd. Q4 Loss Decreases2
03.03.Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update184-Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)- -Achieved Alignment with FDA on Clear and Efficient...
► Artikel lesen
03.03.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer-
19.02.Chemomab Therapeutics: Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis139Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved...
► Artikel lesen
19.02.Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer-
21.08.24Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update185--Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)-- --Establishes...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1